Trial
NCT04170023
Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention
ALXN2050
Why stopped
Did not appropriately control IVH; significantly increased rates of BTH and LDH excursions (LDH excursions is defined by LDH values \> X2ULN) compared to ravulizumab.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-20